Wells Fargo’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,100
| Closed | -$9.93K | – | 7476 |
|
|
2025
Q4 | $9.93K | Buy |
1,100
+1,000
| +1,000% | +$7.47K | ﹤0.01% | 5958 |
|
|
2025
Q3 | $311 | Sell |
100
-528
| -84% | -$1.4K | ﹤0.01% | 6324 |
|
|
2025
Q2 | $1.34K | Sell |
628
-36,350
| -98% | -$58.7K | ﹤0.01% | 6273 |
|
|
2025
Q1 | $42.5K | Sell |
36,978
-4,192
| -10% | -$7.2K | ﹤0.01% | 5453 |
|
|
2024
Q4 | $90.2K | Buy |
41,170
+7,768
| +23% | +$17.6K | ﹤0.01% | 5254 |
|
|
2024
Q3 | $72.8K | Buy |
33,402
+5,363
| +19% | +$12.3K | ﹤0.01% | 5190 |
|
|
2024
Q2 | $64.8K | Buy |
28,039
+13,038
| +87% | +$54.2K | ﹤0.01% | 5182 |
|
|
2024
Q1 | $82.5K | Buy |
15,001
+2,772
| +23% | +$12.7K | ﹤0.01% | 5005 |
|
|
2023
Q4 | $30.2K | Sell |
12,229
-18,256
| -60% | -$173K | ﹤0.01% | 5469 |
|
|
2023
Q3 | $1.06M | Sell |
30,485
-6,643
| -18% | -$230K | ﹤0.01% | 3287 |
|
|
2023
Q2 | $1.22M | Buy |
37,128
+22,398
| +152% | +$772K | ﹤0.01% | 3322 |
|
|
2023
Q1 | $493K | Buy |
14,730
+12,715
| +631% | +$494K | ﹤0.01% | 3862 |
|
|
2022
Q4 | $66.1K | Sell |
2,015
-2,179
| -52% | -$64.5K | ﹤0.01% | 4740 |
|
|
2022
Q3 | $146K | Sell |
4,194
-139
| -3% | -$3.08K | ﹤0.01% | 4413 |
|
|
2022
Q2 | $53K | Buy |
4,333
+1,964
| +83% | +$29.3K | ﹤0.01% | 4997 |
|
|
2022
Q1 | $32K | Sell |
2,369
-3,737
| -61% | -$49.9K | ﹤0.01% | 5848 |
|
|
2021
Q4 | $121K | Buy |
+6,106
| New | +$116K | ﹤0.01% | 5533 |
|
Other funds holding VTYX
Wells Fargo's VTYX Position: Q1 2026 in Review
Wells Fargo sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,100 shares — an estimated $9.93K sold.
Wells Fargo first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $1.22M in Q2 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Wells Fargo reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Wells Fargo sold 1,100 Ventyx Biosciences shares in Q1 2026, an estimated $9.93K.
- Wells Fargo first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Wells Fargo's Ventyx Biosciences position peaked at $1.22M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.